ContractSub-License and Collaboration Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. David A. Vallo Senior Protect Manager MedImmune, LLC...Sub-License and Collaboration Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
Re: Sub-License and Collaboration Agreement dated as of March 20, 2012 (“Agreement”) between MedImmune LLC (“MedImmune”) and Humabs BioMed SA (“Humabs”)
AMENDMENT 2 TO SUB-LICENCE AND COLLABORATION AGREEMENTSub-License and Collaboration Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment (the “Amendment”) to the Sub-License and Collaboration Agreement dated March 20, 2012 (“Agreement”) is entered into effective as of the last date of signature (the “Amendment Effective Date”), by and between MedImmune, LLC, a Delaware limited liability company, with its principal executive offices located at One MedImmune Way, Gaithersburg, MD 20878 (“MedImmune”) and Humabs BioMed SA. a limited company organized under the laws of Switzerland having its head office at Via Mirasloe 1, bellinzona CH-6500 Switzerland (“Humabs”).
AMENDMENT 5 TO SUB-LICENSE AND COLLABORATION AGREEMENTSub-License and Collaboration Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment 5 (the “Amendment”) to the Sub-Licence and Collaboration Agreement dated March 20, 2012, as amended, (the “2012 Agreement”) is entered into and effective as of the last date of signature (the “Amendment Effective Date”), by and between:
